Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02600364 |
|
Recruitment Status :
Completed
First Posted : November 9, 2015
Last Update Posted : November 20, 2020
|
Sponsor:
Phenox GmbH
Information provided by (Responsible Party):
Phenox GmbH
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is to assess safety and effectiveness of the p64 Flow Modulation Device.
| Condition or disease |
|---|
| Intracranial Aneurysm |
Title: Diversion-p64. Device: p64 Flow Modulation Device. Study design: Prospective, multicenter, single arm Post Market Clinical Follow-Up Study.
Purpose: To assess safety and effectiveness of p64. Study duration: 48 months. Sample Size: 400 patients. Number of sites: > 20. Follow-up intervals: Two independent follow-ups (after 3-6 and 7-12 months) according to site specific standard.
| Study Type : | Observational |
| Actual Enrollment : | 450 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Prospective, Multicenter, Single Arm Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device |
| Actual Study Start Date : | December 2015 |
| Actual Primary Completion Date : | June 2020 |
| Actual Study Completion Date : | June 2020 |
Primary Outcome Measures :
- Change in the rate of complete occlusion [ Time Frame: immediately after treatment, an expected average of 1 hour; to 12 months ]Rate of complete aneurysm occlusion is assessed immediately after treatment (an expected average of 1 hour) and at both follow-up visits (3-6 months and 7-12 months). The change is assesed.
- Change of frequency of major stroke (ischemic or hemorrhagic) or neurological death related to the treatment of the target aneurysm [ Time Frame: immediately after treatment, an expected average of 1 hour; to 12 months ]Frequency of major stroke (ischemic or hemorrhagic) or neurological death is assessed immediately after treatment (an expected average of 1 hour) and at both follow-up visits (3-6 months and 7-12 months). The change is assesed.
Secondary Outcome Measures :
- Intra-procedural technical complications [ Time Frame: during treatment, an expected average of 1 hour ]p64 placed in the desired location Correct opening of p64 (markers fully deployed) at the end of the procedure Ability to detach p64 at the end of the procedure
- Change of Angiographic results [ Time Frame: immediately after treatment, an expected average of 1 hour; to 12 months ]Change in both Rate of re-growth (related rate of re-treatment) and Rate of recanalization (related rate of re-treatment) are assessed immediately after treatment (an expected average of 1 hour) and at both follow-up visits (3-6 months and 7-12 months).
- Intra-procedural vascular complications [ Time Frame: during treatment, an expected average of 1 hour ]Vessel perforation (e.g. with distal wire tip of p64, microcatheter) Target aneurysm perforation (e.g. with distal wire tip of p64, microcatheter) Thromboembolism Dissection of any access vessel Side branch occlusion
- Post-procedural Complications [ Time Frame: 3-6 and 7-12 months ]Parenchymal hemorrhage detected during the follow-up period Subarachnoid hemorrhage detected during the follow-up period Ischemic stroke detected on follow-up imaging Rupture of the target aneurysm detected during the follow-up period Rate of in-stent-stenosis detected during the follow-up period
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
The target population for this non-interventional study are patients with ruptured or unruptured aneurysms and segmental diseases in the anterior circulation. Patients can be included in the study if they meet all of the inclusion and none of the exclusion criteria and have provided written informed consent.
Criteria
Inclusion Criteria
- Age ≥ 18
- Patient harbours either one saccular or one dissecting or one blisterlike or one fusiform intracerebral aneurysm or one intracerebral segmental disease, in the anterior circulation for which the indication for p64 treatment is given
- Patient or legal representative provides written informed consent verifying that he/she consents to the use of his/her data (according to the data protection laws)
Exclusion Criteria
- Aneurysms of the posterior circulation
- Imaging evidence of bifurcation aneurysms
- Imaging evidence of dissections
- Imaging evidence of fistulae
- Imaging evidence of arteriovenous malformations
- Patient is harbouring another aneurysm that has to be treated within six months after first procedure
- Known allergy to study medication, e.g. ASA, Clopidogrel, Heparin or contrast media
- Confirmation of positive pregnancy test according to site specific standard of care (e.g. test, verbal communication)
- Current involvement in another study or trial
- Parent vessel treated with other Flow Diverters than p64 during intervention and re-treatment
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02600364
Locations
Show 26 study locations
Sponsors and Collaborators
Phenox GmbH
Investigators
| Principal Investigator: | Alain Bonafé, Prof. Dr. | Hôpital Gui de Chauliac (CHU de Montpellier), Montpellier, France |
Additional Information:
| Responsible Party: | Phenox GmbH |
| ClinicalTrials.gov Identifier: | NCT02600364 |
| Other Study ID Numbers: |
DP64/BO1507 |
| First Posted: | November 9, 2015 Key Record Dates |
| Last Update Posted: | November 20, 2020 |
| Last Verified: | November 2020 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Phenox GmbH:
|
Aneurysm intracerebral stroke p64 |
Additional relevant MeSH terms:
|
Intracranial Aneurysm Aneurysm Vascular Diseases Cardiovascular Diseases Intracranial Arterial Diseases |
Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases |